Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, NC 27157, USA.
Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, NC 27157, USA.
Leuk Res. 2021 Apr;103:106524. doi: 10.1016/j.leukres.2021.106524. Epub 2021 Feb 12.
The azanucleotide decitabine is used in the treatment of acute myeloid leukemia (AML). Studies have shown conflicting results with 10-day regimens used in previously untreated AML patients. Additionally, there is little data on 10-day decitabine regimens in the relapsed setting. This study investigated outcomes of 108 adult patients with AML in the upfront and relapsed setting treated with a 10-day decitabine regimen. In the upfront group, the overall response rate (ORR, CR + CRi) was 36.1% and the median overall survival (OS) was 6.6 months, while the relapsed/refractory group had an ORR of 25% with an OS of 4.8 months. When analyzed with respect to cytogenetics, the upfront group featured an ORR of 28.1% with an OS of 9.4 months in the intermediate cytogenetic cohort compared to a 40.5% ORR and an OS of 5.4 months in the unfavorable cytogenetic cohort. An analysis of the relapsed/refractory group demonstrated an ORR of 26.3% with an OS of 7.9 months for intermediate cytogenetics versus 25.0% with an OS of 1.8 months in the unfavorable cohort. While these response rates are similar to previously published data, the median OS appears shorter.
阿扎核苷酸地西他滨用于治疗急性髓系白血病（AML）。研究表明，在未经治疗的 AML 患者中使用 10 天疗程的结果存在矛盾。此外，在复发环境中，关于 10 天的地西他滨方案的数据很少。这项研究调查了 108 例初治和复发 AML 成年患者接受 10 天地西他滨方案治疗的结果。在初治组中，总缓解率（ORR，完全缓解+完全缓解伴血细胞计数不完全恢复）为 36.1%，中位总生存期（OS）为 6.6 个月，而复发/难治组的 ORR 为 25%，OS 为 4.8 个月。当根据细胞遗传学进行分析时，初治组中间细胞遗传学队列的 ORR 为 28.1%，OS 为 9.4 个月，而不良细胞遗传学队列的 ORR 为 40.5%，OS 为 5.4 个月。对复发/难治组的分析表明，中间细胞遗传学队列的 ORR 为 26.3%，OS 为 7.9 个月，而不良细胞遗传学队列的 ORR 为 25.0%，OS 为 1.8 个月。虽然这些缓解率与先前发表的数据相似，但中位 OS 似乎较短。
